Associated Papers
Complement gene variant effect on relapse of complement-mediated thrombotic microangiopathy after eculizumab cessation.
Acosta-Medina AA et al.
Blood Advances, 2023
35533258 (PubMed )
Supplement: BLOODA_ADV-2021-006416-mmc1.pdf
C3 glomerulonephritis and thrombotic microangiopathy of renal allograft after pulmonary infection in a male with concomitant two complement factor I gene variations: a case report.
Wen J et al.
Bmc Nephrology, 2018
Targeted exome sequencing in anti-factor H antibody negative HUS reveals multiple variations.
Thergaonkar RW et al.
Clinical and Experimental Nephrology, 2018
Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome.
Greenbaum LA et al.
Kidney International, 2016
Thrombotic microangiopathy without renal involvement: two novel mutations in complement-regulator genes.
Peyvandi F et al.
Journal of Thrombosis and Haemostasis : Jth, 2016
Discontinuation of eculizumab treatment in atypical hemolytic uremic syndrome: an update.
Ardissino G et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation, 2015
Select a paper to view details